Extended Data Table 3 ALLO-715 in vivo expansion by DL in patients who received an FCA-containing LD regimen

From: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results